In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi

References

• Patel KP, Vunnam SR, Patel PA, et al. Transmission of SARS-CoV-2: an update of current literature. Eur J Clin Microbiol Infect Dis. 2020;39(11):2005–2011. doi:10.1007/s10096-020-03961-1
   PubMed Web of Science ®Google Scholar
• Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–389. doi:10.1080/22221751.2020.1729071
   PubMed Web of Science ®Google Scholar
• Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. Morb Mortal Wkly Rep. 2020;69(13):382. doi:10.15585/mmwr.mm6913e2
   PubMed Web of Science ®Google Scholar
• Mekonnen D, Mengist HM, Derbie A, et al. Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: a systematic review and meta-analysis. Rev Med Virol. 2021;31:e2181. doi:10.1002/rmv.2181
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–576. doi:10.1002/jmv.25748
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus. Statpearls. Treasure Island (FL): StatPearls PublishingCopyright © 2020, StatPearls Publishing LLC.; 2020.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Eng J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2021;31:e2187. doi:10.1002/rmv.2187
   PubMed Web of Science ®Google Scholar
• Mengist HM, Mekonnen D, Mohammed A, Shi R, Jin T. Potency, safety, and pharmacokinetic profiles of potential inhibitors targeting SARS-CoV-2 main protease. Front Pharmacol. 2021;11:2495. doi:10.3389/fphar.2020.630500
   Web of Science ®Google Scholar
• Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347. doi:10.1038/nrd.2015.37
   PubMed Web of Science ®Google Scholar
• Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(4):853–879. doi:10.1099/0022-1317-81-4-853
   PubMedGoogle Scholar
• Jain R, Mujwar S. Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. Struct Chem. 2020;31(6):2487–2499. doi:10.1007/s11224-020-01605-w
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Kusov Y, et al. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem. 2020;63(9):4562–4578. doi:10.1021/acs.jmedchem.9b01828
   PubMed Web of Science ®Google Scholar
• Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281(18):4085–4096. doi:10.1111/febs.12936
   PubMed Web of Science ®Google Scholar
• Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α‐helical domain. EMBO J. 2002;21(13):3213–3224. doi:10.1093/emboj/cdf327
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763–1767. doi:10.1126/science.1085658
   PubMed Web of Science ®Google Scholar
• Xue X, Yang H, Shen W, et al. Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J Mol Biol. 2007;366(3):965–975. doi:10.1016/j.jmb.2006.11.073
   PubMed Web of Science ®Google Scholar
• Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Nat Acad Sci. 2003;100(23):13190–13195. doi:10.1073/pnas.1835675100
   PubMed Web of Science ®Google Scholar
• Shi J, Wei Z, Song J. Dissection Study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem. 2004;279(23):24765–24773. doi:10.1074/jbc.M311744200
   PubMed Web of Science ®Google Scholar
• Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS. 2015;7:95–104.
   Google Scholar
• de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis. 2017;5:Doc08–Doc. doi:10.3205/id000034
   PubMedGoogle Scholar
• Thiel V, Ivanov KA, Putics A, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol. 2003;84(9):2305–2315. doi:10.1099/vir.0.19424-0
   PubMed Web of Science ®Google Scholar
• Shu T, Huang M, Wu D, et al. SARS-coronavirus-2 Nsp13 possesses NTPase and RNA helicase activities that can be inhibited by bismuth salts. Virol Sin. 2020;35(3):321–329. doi:10.1007/s12250-020-00242-1
   PubMed Web of Science ®Google Scholar
• Mengist HM, Dilnessa T, Jin T. Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front Chem. 2021;9:622898. doi:10.3389/fchem.2021.622898
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409–412. doi:10.1126/science.abb3405
   PubMed Web of Science ®Google Scholar
• Mengist HM, Fan X, Jin T. Designing of improved drugs for COVID-19: crystal structure of SARS-CoV-2 main protease Mpro. Signal Transduct Target Ther. 2020;5(1):67. doi:10.1038/s41392-020-0178-y
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293. doi:10.1038/s41586-020-2223-y
   PubMed Web of Science ®Google Scholar
• Jin Z, Zhao Y, Sun Y. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27(6):529–532. doi:10.1038/s41594-020-0440-6
   PubMed Web of Science ®Google Scholar
• Sies H, Parnham MJ. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol Med. 2020;156:107–112. doi:10.1016/j.freeradbiomed.2020.06.032
   PubMed Web of Science ®Google Scholar
• Dai W, Zhang B, Jiang X-M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331–1335. doi:10.1126/science.abb4489
   PubMed Web of Science ®Google Scholar
• Rathnayake AD, Zheng J, Kim Y. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci Transl Med. 2020;12(557):eabc5332. doi:10.1126/scitranslmed.abc5332
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X-J. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020;47(2):119–121. doi:10.1016/j.jgg.2020.02.001
   PubMed Web of Science ®Google Scholar
• Li Z, Li X, Huang -Y-Y, et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc Nat Acad Sci. 2020;117(44):27381–27387. doi:10.1073/pnas.2010470117
   PubMed Web of Science ®Google Scholar
• Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020;10(7):1205–1215. doi:10.1016/j.apsb.2020.04.008
   PubMed Web of Science ®Google Scholar
• Vuong W, Khan MB, Fischer C. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020;11(1):4282. doi:10.1038/s41467-020-18096-2
   PubMed Web of Science ®Google Scholar
• Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. bioRxiv Preprint 20200420051581; 2020.
   Google Scholar
• Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786. doi:10.1016/j.antiviral.2020.104786
   PubMed Web of Science ®Google Scholar
• Abel R, Chen Q, Paredes Ramos M, et al. Computational prediction of potential inhibitors of the main protease of SARS-CoV-2. Front Chem. 2020;8:1162. doi:10.3389/fchem.2020.590263
   Web of Science ®Google Scholar
• Selvaraj C, Panwar U, Dinesh DC, et al. Microsecond MD simulation and multiple-confirmation virtual screening to identify potential anti-COVID-19 inhibitors against SARS-CoV-2 main protease. Front Chem. 2020;8:1179.
   Web of Science ®Google Scholar
• Ul Qamar MT, Alqahtani SM, Alamri MA, Chen -L-L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313–319. doi:10.1016/j.jpha.2020.03.009
   PubMed Web of Science ®Google Scholar
• More-Adate P, Lokhande KB, Swamy KV, Nagar S, Baheti A. GC-MS profiling of Bauhinia variegata major phytoconstituents with computational identification of potential lead inhibitors of SARS-CoV-2 M(pro). Comput Biol Med. 2022;147:105679. doi:10.1016/j.compbiomed.2022.105679
   PubMed Web of Science ®Google Scholar
• Lokhande K, Nawani N, Pawar S, Pawar S. Biflavonoids from Rhus succedanea as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach. J Biomol Struct Dyn. 2022;40(10):4376–4388. doi:10.1080/07391102.2020.1858165
   PubMed Web of Science ®Google Scholar
• Pandey K, Lokhande KB, Swamy KV, Nagar S, Dake M. In silico exploration of phytoconstituents from phyllanthus emblica and aegle marmelos as potential therapeutics against SARS-CoV-2 RdRp. Bioinform Biol Insights. 2021;15:11779322211027403. doi:10.1177/11779322211027403
   Web of Science ®Google Scholar
• Pulakuntla S, Lokhande KB, Padmavathi P, et al. Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach. Virusdisease. 2021;32(4):690–702. doi:10.1007/s13337-021-00720-4
   PubMedGoogle Scholar
• Ferraz WR, Gomes RA, Novaes AL, Goulart Trossini GH. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study. Future Med Chem. 2020;12(20):1815–1828. doi:10.4155/fmc-2020-0165
   PubMed Web of Science ®Google Scholar
• Kanhed AM, Patel DV, Teli DM, Patel NR, Chhabria MT, Yadav MR. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach. Mol Divers. 2020;25:383–401. doi:10.1007/s11030-020-10130-1
   PubMed Web of Science ®Google Scholar
• Palese LL The structural landscape of SARS-CoV-2 main protease: hints for inhibitor search. ChemRxiv Preprint; 2020.
   Google Scholar
• Baby K, Maity S, Mehta CH, Suresh A, Nayak UY, Nayak Y. Targeting SARS-CoV-2 main protease: a computational drug repurposing study. Arch Med Res. 2020;52:38–47.
   PubMed Web of Science ®Google Scholar
• Batool F, Mughal EU, Zia K, et al. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. J Biomol Struct Dyn. 2020;5:1–12.
   Google Scholar
• Belaqziz R, Harrak R, Romane A, Oufdou K, ElFels MAE. Antimicrobial and insecticidal activities of the endemic thymus broussonetti boiss. and thymus maroccanus ball. Rec Nat Prod. 2010;4(4):230.
   Google Scholar
• Damtie D, Mekonnen Y. Thymus species in Ethiopia: distribution, medicinal value, economic benefit, current status and threatening factors. Ethiop Sci Technol. 2015;8(2):81–92. doi:10.4314/ejst.v8i2.3
   Google Scholar
• Adane F, Asres K, Ergete W, et al. Composition of the essential oil Thymus schimperi and evaluation of its acute and subacute toxicity in Wistar albino rats: in silico toxicity studies. Evid Based Complement Altern Med. 2021;2021:1. doi:10.1155/2021/5521302
   Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102–D9. doi:10.1093/nar/gky1033
   PubMed Web of Science ®Google Scholar
• Mendelsohn LD. ChemDraw 8 Ultra, Windows and Macintosh versions. J Chem Inf Comput Sci. 2004;44(6):2225–2226. doi:10.1021/ci040123t
   Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):1–13. doi:10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–W63. doi:10.1093/nar/gky318
   PubMed Web of Science ®Google Scholar
• Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model. 1999;17(1):57–61.
   PubMed Web of Science ®Google Scholar
• Huey R, Morris GM, Forli S. Using AutoDock 4 and AutoDock vina with AutoDockTools: a tutorial. Scripps Res Inst Mol Graphics Lab. 2012;10550:92037.
   Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791. doi:10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Hsu M-F, Kuo C-J, Chang K-T, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem. 2005;280(35):31257–31266. doi:10.1074/jbc.M502577200
   PubMed Web of Science ®Google Scholar
• Chou C-Y, Chang H-C, Hsu W-C, Lin T-Z, Lin C-H, Chang -G-G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry. 2004;43(47):14958–14970. doi:10.1021/bi0490237
   PubMed Web of Science ®Google Scholar
• Swiderek K, Moliner V. Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro from QM/MM computational methods. Chem Sci. 2020;11:10626–10630. doi:10.1039/D0SC02823A
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel. 1995;8(2):127–134. doi:10.1093/protein/8.2.127
   Web of Science ®Google Scholar
• Vanommeslaeghe K, Hatcher E, Acharya C, et al. CHARMM general force field: a force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields. J Comput Chem. 2010;31(4):671–690. doi:10.1002/jcc.21367
   PubMed Web of Science ®Google Scholar
• Karplus M, Petsko GAJN. Molecular dynamics simulations in biology. Nature. 1990;347(6294):631–639. doi:10.1038/347631a0
   PubMed Web of Science ®Google Scholar
• Galindez G, Matschinske J, Rose TD, et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat Comput Sci. 2021;1(1):33–41. doi:10.1038/s43588-020-00007-6
   PubMedGoogle Scholar
• Bhuiyan FR, Howlader S, Raihan T, Hasan M. Plants metabolites: possibility of natural therapeutics against the COVID-19 pandemic. Front Med. 2020;7:444. doi:10.3389/fmed.2020.00444
   PubMed Web of Science ®Google Scholar
• Qamar M, Maryam A, Muneer I, et al. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. Sci Rep. 2019;9:1433. doi:10.1038/s41598-018-38450-1
   PubMed Web of Science ®Google Scholar
• Sinha SK, Prasad SK, Islam MA, et al. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study. J Biomol Struct Dyn. 2021;39(13):4686–4700. doi:10.1080/07391102.2020.1779132
   PubMed Web of Science ®Google Scholar
• Patel CN, Jani SP, Jaiswal DG, et al. Identification of antiviral phytochemicals as a potential SARS-CoV-2 main protease (M(pro)) inhibitor using docking and molecular dynamics simulations. Sci Rep. 2021;11(1):20295. doi:10.1038/s41598-021-99165-4
   PubMed Web of Science ®Google Scholar
• Srivastav AK, Gupta SK, Kumar U Computational studies towards identification of lead herbal compounds of medicinal importance for development of nutraceutical against COVID-19; 2021.
   Google Scholar
• Kumar A, Choudhir G, Shukla SK, et al. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. J Biomol Struct Dyn. 2021;39(10):3760–3770. doi:10.1080/07391102.2020.1772112
   PubMed Web of Science ®Google Scholar
• Ebada SS, Al-Jawabri NA, Youssef FS, et al. Anti-inflammatory, antiallergic and COVID-19 protease inhibitory activities of phytochemicals from the Jordanian hawksbeard: identification, structure–activity relationships, molecular modeling and impact on its folk medicinal uses. RSC Adv. 2020;10(62):38128–38141. doi:10.1039/D0RA04876C
   PubMed Web of Science ®Google Scholar
• Martin YC. A bioavailability score. J Med Chem. 2005;48(9):3164–3170. doi:10.1021/jm0492002
   PubMed Web of Science ®Google Scholar
• Abdul-Hammed M, Adedotun IO, Olajide M, et al. Virtual screening, ADMET profiling, PASS prediction, and bioactivity studies of potential inhibitory roles of alkaloids, phytosterols, and flavonoids against COVID-19 main protease (M(pro)). Nat Prod Res. 2022;36(12):3110–3116. doi:10.1080/14786419.2021.1935933
   PubMed Web of Science ®Google Scholar
• Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 2009;1(1):8. doi:10.1186/1758-2946-1-8
   PubMed Web of Science ®Google Scholar
• Sisakht M, Mahmoodzadeh A, Darabian M. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study. Phytother Res. 2021;35(6):3262–3274. doi:10.1002/ptr.7041
   PubMed Web of Science ®Google Scholar
• Ullah S, Munir B, Al-Sehemi AG, et al. Identification of phytochemical inhibitors of SARS-CoV-2 protease 3CLpro from selected medicinal plants as per molecular docking, bond energies and amino acid binding energies. Saudi J Biol Sci. 2022;29(6):103274. doi:10.1016/j.sjbs.2022.03.024
   PubMed Web of Science ®Google Scholar
• Mahmud S, Hasan MR, Biswas S, et al. Screening of Potent phytochemical inhibitors against SARS-CoV-2 main protease: an integrative computational approach. Front Bioinform. 2021;1:1. doi:10.3389/fbinf.2021.717141
   Google Scholar
• Shree P, Mishra P, Selvaraj C, et al. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants – withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study. J Biomol Struct Dyn. 2022;40(1):190–203. doi:10.1080/07391102.2020.1810778
   PubMed Web of Science ®Google Scholar
• Dey D, Hossain R, Biswas P, et al. Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology. Mol Divers. 2022;2022:1.
   Google Scholar
• Chatterjee S, Maity A, Chowdhury S, Islam MA, Muttinini RK, Sen D. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme. J Biomol Struct Dyn. 2021;39(14):5290–5303. doi:10.1080/07391102.2020.1787228
   PubMed Web of Science ®Google Scholar
• Mahmud S, Uddin MAR, Paul GK, et al. Virtual screening and molecular dynamics simulation study of plant-derived compounds to identify potential inhibitors of main protease from SARS-CoV-2. Brief Bioinform. 2021;22(2):1402–1414. doi:10.1093/bib/bbaa428
   PubMed Web of Science ®Google Scholar
• Swargiary A, Mahmud S, Saleh MA. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19. J Biomol Struct Dyn. 2022;40(5):2067–2081. doi:10.1080/07391102.2020.1835729
   PubMed Web of Science ®Google Scholar
• Mousavi SS, Karami A, Haghighi TM, et al. In silico evaluation of Iranian medicinal plant phytoconstituents as inhibitors against main protease and the receptor-binding domain of SARS-CoV-2. Molecules. 2021;26(18):5724. doi:10.3390/molecules26185724
   PubMed Web of Science ®Google Scholar
• Tallei TE, Tumilaar SG, Niode NJ, et al. Potential of plant bioactive compounds as SARS-CoV-2 main protease (Mpro) and spike (S) glycoprotein inhibitors: a molecular docking study. Scientifica. 2020;2020:2. doi:10.1155/2020/6307457
   Web of Science ®Google Scholar
• Mahmud S, Paul GK, Afroze M, et al. Efficacy of phytochemicals derived from Avicennia officinalis for the management of COVID-19: a combined in silico and biochemical study. Molecules. 2021;26(8):2210. doi:10.3390/molecules26082210
   PubMed Web of Science ®Google Scholar
• Mahmud S, Afrose S, Biswas S, et al. Plant-derived compounds effectively inhibit the main protease of SARS-CoV-2: an in silico approach. PLoS One. 2022;17(8):e0273341. doi:10.1371/journal.pone.0273341
   PubMed Web of Science ®Google Scholar
• Teli DM, Shah MB, Chhabria MT. In silico screening of natural compounds as potential inhibitors of SARS-CoV-2 main protease and spike RBD: targets for COVID-19. Front Mol Biosci. 2021;7:4. doi:10.3389/fmolb.2020.599079
   Web of Science ®Google Scholar
• Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47(12):3907–3916. doi:10.1128/AAC.47.12.3907-3916.2003
   PubMed Web of Science ®Google Scholar
• Kim Y, Liu H, Galasiti Kankanamalage AC, et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 2016;12(3):e1005531. doi:10.1371/journal.ppat.1005531
   PubMed Web of Science ®Google Scholar
• Yang H, Xie W, Xue X, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3(10):e324. doi:10.1371/journal.pbio.0030324
   PubMed Web of Science ®Google Scholar
• Khalid Z, Mannan SJP, Biology A. Revealing potential drug targets against Proto-oncogene Wnt10B by comparative molecular docking. Pure Appl Biol. 2018;7(2):565–574. doi:10.19045/bspab.2018.70070
   Google Scholar
• Mangrio GR, Maneengam A, Khalid Z, et al. RP-HPLC method development, validation, and drug repurposing of sofosbuvir pharmaceutical dosage form: a multidimensional study. Environ Res. 2022;212:113282. doi:10.1016/j.envres.2022.113282
   PubMed Web of Science ®Google Scholar
• Ibrahim MAA, Abdelrahman AHM, Hussien TA, et al. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput Biol Med. 2020;126:104046. doi:10.1016/j.compbiomed.2020.104046
   PubMed Web of Science ®Google Scholar
• Nasir M, Tafess K, Abate D. Antimicrobial potential of the Ethiopian Thymus schimperi essential oil in comparison with others against certain fungal and bacterial species. BMC Complement Altern Med. 2015;15(1):260. doi:10.1186/s12906-015-0784-3
   PubMed Web of Science ®Google Scholar
• Damtie D, Mekonnen Y. Antibacterial activity of essential oils from Ethiopian thyme (Thymus serrulatus and Thymus schimperi) against tooth decay bacteria. PLoS One. 2020;15(10):e0239775. doi:10.1371/journal.pone.0239775
   PubMedGoogle Scholar
• Di Matteo G, Spano M, Grosso M, et al. Food and COVID-19: preventive/co-therapeutic strategies explored by current clinical trials and in silico studies. Foods. 2020;9(8):1036. doi:10.3390/foods9081036
   PubMed Web of Science ®Google Scholar